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Abstract 
It is estimated that inflammatory diseases affect more than 80 million people 
worldwide and these numbers are expected to increase in the next 20 years. Disorders 
such as rheumatoid arthritis (RA) can shorten life span by 10 years and its treatment 
remains a challenge for the medical and scientific community. More efficient strategies 
are required in order to improve clinical benefit. Nano-enabled drug delivery systems 
aim to improve therapy of chronic inflammatory disorders by creating a new, highly 
specific and efficient strategy, with reduced treatment costs. 
The consortium of NANOFOL FP7 project produced FBN (liposomal, protein-based and 
PLA (poly (L-lactic acid)) nanoparticles) with encapsulated anti-inflammatory drugs that 
were  shown to be biologically active, non cytotoxic and capable of specifically 
targeting folate receptor (FR)-positive cells, in particular activated macrophages, 
mediators of chronic inflammation in RA.  The NANOFOL nanobiodevices targeting 
activated macrophages may be an interesting theranostics  solution, i.e., simultaneous  
diagnosis and treatment of the site of inflammation in RA patients. The production of a 
validated, stable, specific FBN with incorporated imaging agent and therapeutic agent 
(drugs or siRNAs) by the NANOFOL consortium will have many applications in all 
inflammatory diseases but may also extend to cancer treatment. 
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